| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | LAGEVRIO - (Molnupiravir) | COVID-19 | Phase 3 | oral | COVID-19 | |
| Merck & Company Inc. | V940-001 (mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-002) | Personalized cancer vaccine, high-risk melanoma, lung cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) - KN-604 | Small cell lung cancer (SCLC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) | Triple negative breast cancer (TNBC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) - KN-240 | Hepatocellular Carcinoma | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) KN-062 | Gastric cancer | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | Rezafungin (CD101) ReSPECT | Prophylaxis | Phase 3 | Intravenous | N/A | |
| Merck & Company Inc. | LYNPARZA (olaparib) - (OlympiA) | Early Breast Cancer | Phase 3 | Data Released | oral | Oncology |